5 August 2020 - Compassionate use Special Access Scheme approval for Alzheimer’s patients to continue treatment with Anavex 2-73 (blarcamesine) after completing the 5 year Anavex 2-73-003 Phase 2a clinical study.

Anavex Life Sciences  today announced that patients from the Anavex 2-73-003 phase 2a Alzheimer’s disease trial will continue treatment with Anavex 2-73 (blarcamesine) via the Australian Government Department of Health - Therapeutic Goods Administration compassionate use Special Access Scheme following completion of over 5 years daily dosing of Anavex 2-73 (blarcamesine) and recommendation by their physicians.